IO Biotech expands collaboration with MSD – begins phase II trial
![Mai-Britt Zocca, CEO and founder of IO Biotech, has signed off on the Danish cancer company's third deal with US-based MSD | Photo: IO Biotech / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13532643.ece/ALTERNATES/schema-16_9/doc7iq2nh3gqig1chnldmfa.jpg)
Danish cancer company IO Biotech is entering its third clinical collaboration with US-based pharmaceutical giant MSD. The ambition is to develop a drug for the treatment of three different types of cancer, it reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
IO Biotech begins phase III trial with partner MSD
For subscribers
MSD Covid-19 treatment less effective than first thought
For subscribers